At the 44th Annual J.P. Morgan Healthcare Conference, Integra LifeSciences President and CEO Mojdeh Poul marked her first appearance in the role, emphasizing the company’s leading positions in global neurosurgery and tissue technologies. She noted that Integra holds the number one or two ranking in every neurosurgery category it serves and highlighted the strong clinical preferences for its advanced wound-care and reconstructive products, which consistently deliver superior patient outcomes.

In its latest quarterly report, Integra posted EPS of $0.54, exceeding consensus by $0.11, on revenue of $402.1 million, up 5.6% year-over-year but slightly below analyst expectations. The company reported a negative net margin of 30.2% and a return on equity of 14.1%. Management set Q4 EPS guidance of $0.79–$0.84 and full-year EPS guidance of $2.19–$2.24, compared with the current analyst consensus of $2.45 for the fiscal year.

Among seven research firms covering Integra, three have issued sell ratings, two maintain holds and two carry buy recommendations, resulting in an average 12-month price target of $15.00. Insider buying was highlighted by a director who acquired 9,000 shares, boosting his stake by 28.1%. Institutional investors now own 84.8% of the company’s shares, with notable position increases recorded by several global asset managers over the past quarter.